38 results about "Eye posterior segment" patented technology

Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

The invention provides methods for delivering bioactive agent to an eye, the methods including steps of providing a device at an implantation site within the eye, and maintaining the device at the implantation site to provide a therapeutically effective amount of the bioactive agent to the eye. The device includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension. A polymeric coated composition is provided in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The invention also provides methods of administering a therapeutically effective amount of bioactive agent to a posterior segment of an eye.

The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and / or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and / or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome.

The invention discloses an implantable intraocular quantitative medicine injection pump which comprises a medicine guiding pipe and a medicine adding bag, wherein a medicine inlet and a medicine outlet are arranged on the medicine adding bag, and one end of the medicine guiding pipe is communicated with the medicine outlet. While in use, the medicine adding bag is filled with medicine liquid and is punctured at the cornea segment, the medicine guiding pipe is inserted, the medicine adding bag is extruded, and the medicine liquid flows into the vitreous body through the medicine guiding pipe. The capacity of the medicine adding bag can be designed into a quantity required for single medication, an operator does not require repeating measuring medicine quantity during each medication, and the working efficiency is increased. The device can quantitatively medicate the eye posterior segment for multiple times without intraocular operation, is safe for implantation and easy for taking out, can reduce intraocular infection risk, can realize long-term sustainable medication to form effective medicine concentration and can enhance the local curative effects of the medicine in the eyes. The purpose of treating a series of intractable eye diseases requiring overall or local frequent medication is achieved, and the invention has great economical and social benefits and is very applicable to clinic application.

The invention relates to a method for discriminating acanthopagrus schlegelii, pagrosomus major and hybrid offsprings thereof based on morphological parameters. The method includes the following steps that the morphological parameters of a sparidae sample are measured, wherein the morphological parameters comprise total length, body length, body thickness, eye diameter and eye posterior segment length; discriminant equations for an acanthopagrus schlegelii selfing group, a pagrosomus major selfing group, a female pagrosomus major and male acanthopagrus schlegelii hybridization group and a female acanthopagrus schlegelii and male pagrosomus major hybridization group are established; the obtained morphological parameters are substituted into the discriminant equation set to determine fish varieties. By means of the method, acanthopagrus schlegelii, pagrosomus major and hybrid offsprings thereof can be rapidly and accurately discriminated.

Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

An ophthalmic measurement system and method are used for detecting checked eyes. The ophthalmic measurement system includes a switching scanning element, an eye anterior segment light path assembly, an eye posterior segment light path assembly, a light splitting element and a main body module. An optical path can be switched between the eye anterior segment light path assembly and the eye posterior segment light path assembly by the switching scanning element, and an eye anterior segment and an eye posterior segment of the checked eyes are scanned. The invention provides another technical scheme which can realize the switching of scanning of the eye anterior segment and the eye posterior segment of the checked eyes to determine the axis length of the checked eyes, and the disadvantages ofcomplex structure and high cost of the prior art are overcome.

The invention discloses a hyaluronic acid derivative and a preparation method thereof, wherein the hyaluronic acid derivative is obtained via covalent combination of a phenolic hydroxyl group-containing isoquinoline compound with hyaluronic acid via intracorporal degradable molecular bridges. The hyaluronic acid derivative can be used for preparing medicines used for nonoral administration, and especially used for preparing slow-release medicines which are used for treating related diseases via articular cavity and eye posterior segment topical administration; and is excellent in curative effect; and toxic and side effect is less.

The present invention relates to topical formulations comprising a compound of the following formula:for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w / v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and / or the choroid.

The invention discloses an eye posterior segment laser contact lens stabilizing device, and relates to a medical instrument. The device specifically comprises a pedestal and a fixed rod installed on the pedestal, a vertical lifting rod is installed on the fixed rod, and a top plate is welded and fixed to the top end of the lifting rod. The bottom face of the top plate is fixedly connected with anupper chuck installed on the lifting rod through a first spring, the upper chuck is meshed with a lower chuck installed on the rotating plate, a sliding rod is installed on the side face of the rotating plate, one end of the sliding rod stretches into the rotating plate and is in sliding connection with the rotating plate, and an installation plate is fixedly welded to the other end of the slidingrod. A rotating block is rotationally installed on the side face of the installation plate, the side face of the rotating block is hinged to one end of a rotating arm through a pin, and a clamp usedfor clamping the contact lens is fixed to the other end of the rotating arm. According to the technical scheme, the contact lens fixing device is more stable and effective during fixing, even if a person accidentally touches the stabilizing device, excessive influence is avoided, and the fixing effect on the contact lens is improved.

The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.

The invention provides an ophthalmic preparation for treating macular edema, optic neuritis and non-infectious entophthalmia. The ophthalmic preparation is composed of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material; the active ingredientfor treating the eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine; the ophthalmic preparation carrier or auxiliary material comprises the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with medium polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of the eye and be conveyed to the posterior segment of the eye to treat the macular edema, the optic neuritis and the non-infectious entophthalmiain an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and very positive social significance.

The invention relates to photosensitive type vitreous injectable gel as well as a preparation method and application thereof. The photosensitive type vitreous injectable gel is prepared from a bulk drug, a photosensitive material, upconversion nanoparticles (UCNPs) and water, wherein the bulk drug is prepared by compounding a traditional Chinese medicine active ingredient for inhibiting angiogenesis-oxidative stress and a traditional Chinese medicine active ingredient for promoting autophagy of retinal pigment epithelium (RPE); and the photosensitive material is hyaluronic acid in which a carboxyl group is covalently connected with a photosensitive group. The efficacy of treating age-related macular degeneration is enhanced through reasonable natural medicine combination; and the medicine delivery capacity of the posterior segment of the eye is improved by assembling a proper medicine delivery system, CNV formation is jointly inhibited from the two aspects of treatment medicine combination and medicine delivery efficiency, pathogenic signals are blocked in multiple links, and AMD treatment effect is improved.

A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and / or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.

The invention discloses a pressure regulating device for a posterior segment of eyes in penetrating keratoplasty. The pressure regulating device comprises a negative pressure machine, a liquid suctionneedle and a connecting pipe, wherein a first pipe connector is arranged on the negative pressure machine, a second pipe connector is arranged at the tail of the liquid suction needle, one end of theconnecting pipe is connected with the first pipe connector, and the other end of the connecting pipe is connected with the second pipe connector; and a pressure regulating knob is arranged on the negative pressure machine. Compared with the prior art, according to the technical scheme, the intraocular pressure in the penetrating keratoplasty can be accurately controlled, the eyeball content is prevented from being extruded outwards, and the device is easy to operate, adjustable and controllable in pressure, reliable and stable and can ensure safety in the penetrating keratoplasty, reduce theoperation difficulty and avoid serious complications such as disengagement of the eyeball content.

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

The invention relates to a new therapeutic approach for treatment and / or prevention of a disease of the posterior segment of the eye, in particular for retinal and optic nerve pathologies. Dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, are proposed for use topically administered onto eye surface. There are also disclosed new compositions comprising dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, adapted for performing the treatment and / or prevention of diseases of the posterior segment of the eye.

The present invention concerns nanoparticles useful for treating posterior segment ocular diseases or conditions, such as macular degeneration and diabetic retinopathy; compositions comprising the nanoparticles; methods for producing the nanoparticles; and methods for treating posterior segment ocular diseases or conditions, comprising administering the nanoparticles or compositions to the ocular posterior segment of an afflicted eye.

The invention discloses an implantable intraocular quantitative medicine injection pump which comprises a medicine guiding pipe and a medicine adding bag, wherein a medicine inlet and a medicine outlet are arranged on the medicine adding bag, and one end of the medicine guiding pipe is communicated with the medicine outlet. While in use, the medicine adding bag is filled with medicine liquid and is punctured at the cornea segment, the medicine guiding pipe is inserted, the medicine adding bag is extruded, and the medicine liquid flows into the vitreous body through the medicine guiding pipe. The capacity of the medicine adding bag can be designed into a quantity required for single medication, an operator does not require repeating measuring medicine quantity during each medication, and the working efficiency is increased. The device can quantitatively medicate the eye posterior segment for multiple times without intraocular operation, is safe for implantation and easy for taking out,can reduce intraocular infection risk, can realize long-term sustainable medication to form effective medicine concentration and can enhance the local curative effects of the medicine in the eyes. The purpose of treating a series of intractable eye diseases requiring overall or local frequent medication is achieved, and the invention has great economical and social benefits and is very applicableto clinic application.

The present invention relates to a prophylactic or therapeutic agent for diseases of the posterior segment of the eye, which contains, as an active ingredient, a compound represented by formula (1), an enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof (hereinafter referred to as "the present compound").

An ophthalmic formulation comprising transethosomes is provided. The transethosomes include a phospholipid, an edge activator, ethanol, and ketoconazole, wherein a surface of the transethosome is modified with a cationic charge inducing agent. The transethosomes may be incorporated into in situ gelling or hydrogel compositions. The formulations are useful for the sustained delivery of ketoconazole to the posterior eye segment of a subject.

A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and / or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.

The invention relates to a new therapeutic approach for the treatment and / or prevention of a disease of the posterior segment of the eye, in particular for retinal and optic nerve pathologies. Dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, are proposed for use topically administered onto eye surface. There are also disclosed new compositions comprising dobesilic acid and / or a pharmaceutically acceptable salt, or an ester of any of the acid or the salt, adapted for performing the treatment and / or prevention of diseases of the posterior segment of the eye.

The invention provides an ophthalmic preparation for preventing and treating dry maculopathy and retina light damage. The ophthalmic preparation consists of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material; the active ingredient for treating eye diseases is an adenylate activated protein kinase activator and / or an anti-inflammatory active ingredient; and the ophthalmic preparation carrier or auxiliary material comprises the following ingredients: a surfactant, an ionic polymer and a solvent. The ophthalmic preparation can carry (wrap) the adenylate activated protein kinase activator and / or the anti-inflammatory active ingredient to penetrate through the anterior segment of the eye and be conveyed to the posterior segment of the eye to prevent and treat dry maculopathy and retina light damage in an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and very positive social significance.